Prospective Study to Compare Results of STN-DBS Between Early Treated and Late-treated PD Patient

NCT ID: NCT01274832

Last Updated: 2011-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-02-28

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the impact of DBS not only no motor outcomes, but also on neuropsychological and psychiatric aspects and on quality of life in young patients with a short history of disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bilateral STN DBS is a powerful treatment for advanced Parkinson disease with Levodopa induced motor complications. The beneficial effects of STN stimulation on motor disability and quality of life have been proved. However, the mean delay before neurosurgery is currently 14 years after diagnosis, when medical treatment no longer controls PD symptoms and quality of life is already severely impaired.

Aim of this study is to prospectively assess the effects of bilateral STN stimulation on motor signs, psychological and psychiatric aspects and quality of life in a group of 20 patients with PD who underwent surgery after 5 years from the onset of the disease. These results will be compared with those of a group of 20 patients with a PD history from more than 10 years.

The two groups of patients will be evaluated at baseline and after 3 and 12 months from DBS implant; at each visit neurological and motor examinations were assessed and dedicated neuropsychological and psychiatric tests will be performed.

Neurosurgery may be considered superior to medical treatment alone even in mild to moderate PD of 10 years duration, rather than a last resort in very advanced stages of the disease. Thanks to this study we could compare motor outcomes and cognitive aspects between DBS patients with a short and with long history of disease

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease DBS Deep Brain Stimulation STN

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Late-treated PD patients

Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease \> 10 years

Deep Brain Stimulation

Intervention Type DEVICE

Deep Brain Stimulation of STN in Parkinsonian patients

Early-treated PD patients

Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease \<7 years

Deep Brain Stimulation

Intervention Type DEVICE

Deep Brain Stimulation of STN in Parkinsonian patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deep Brain Stimulation

Deep Brain Stimulation of STN in Parkinsonian patients

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DBS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* suffering from PD of \> 10 years and with LTS (long term L-dopa syndrome), or with a duration of PD of 5 years
* age\< 70 years
* normal brain MRI
* absence of dementia (Mini Mental State Examination ≥ 24)
* absence of severe psychiatric diseases
* Signed informed consent form
* Absence of allergy to metal
* Italian native speaker
* Absence of communicative or perceptive deficits

Exclusion Criteria

* Any form of familiar PD
* Presence of neoplasia
* Presence of HIV
* Presence of severe metabolic diseases
* Severe cardiac/respiratory/renal or hepatic diseases
* Ongoing treatment with immunodepressive/ immunomodulate drugs
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Associazione Italiana Parkinsoniani (AIP)- Sezione Bergamo

UNKNOWN

Sponsor Role collaborator

A.O. Ospedale Papa Giovanni XXIII

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Azienda Ospedaliera Ospedali Riuniti di Bergamo

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bruno Ferraro, MD

Role: PRINCIPAL_INVESTIGATOR

Azienda Ospedaliera Ospedali Riuniti di Bergamo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Azienda Ospedaliera Ospedali Riuniti di Bergamo

Bergamo, Lombardy, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bruno Ferraro, MD

Role: CONTACT

0039035269411

Dario Alimonti, MD

Role: CONTACT

0039035269414

References

Explore related publications, articles, or registry entries linked to this study.

Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med. 1998 Oct 8;339(15):1044-53. doi: 10.1056/NEJM199810083391506. No abstract available.

Reference Type BACKGROUND
PMID: 9761807 (View on PubMed)

Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain. 2000 Nov;123 ( Pt 11):2297-305. doi: 10.1093/brain/123.11.2297.

Reference Type BACKGROUND
PMID: 11050029 (View on PubMed)

Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, Lang AE. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology. 1998 Sep;51(3):850-5. doi: 10.1212/wnl.51.3.850.

Reference Type BACKGROUND
PMID: 9748038 (View on PubMed)

Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology. 1999 Jul 13;53(1):85-90. doi: 10.1212/wnl.53.1.85.

Reference Type BACKGROUND
PMID: 10408541 (View on PubMed)

Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology. 2002 Feb 12;58(3):396-401. doi: 10.1212/wnl.58.3.396.

Reference Type BACKGROUND
PMID: 11839838 (View on PubMed)

Deep-Brain Stimulation for Parkinson's Disease Study Group; Obeso JA, Olanow CW, Rodriguez-Oroz MC, Krack P, Kumar R, Lang AE. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001 Sep 27;345(13):956-63. doi: 10.1056/NEJMoa000827.

Reference Type BACKGROUND
PMID: 11575287 (View on PubMed)

Houeto JL, Damier P, Bejjani PB, Staedler C, Bonnet AM, Arnulf I, Pidoux B, Dormont D, Cornu P, Agid Y. Subthalamic stimulation in Parkinson disease: a multidisciplinary approach. Arch Neurol. 2000 Apr;57(4):461-5. doi: 10.1001/archneur.57.4.461.

Reference Type BACKGROUND
PMID: 10768618 (View on PubMed)

Mesnage V, Houeto JL, Welter ML, Agid Y, Pidoux B, Dormont D, Cornu P. Parkinson's disease: neurosurgery at an earlier stage? J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):778-9. doi: 10.1136/jnnp.73.6.778. No abstract available.

Reference Type BACKGROUND
PMID: 12438494 (View on PubMed)

Carlesimo GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol. 1996;36(6):378-84. doi: 10.1159/000117297.

Reference Type BACKGROUND
PMID: 8954307 (View on PubMed)

Volkmann J. Deep brain stimulation for the treatment of Parkinson's disease. J Clin Neurophysiol. 2004 Jan-Feb;21(1):6-17. doi: 10.1097/00004691-200401000-00003.

Reference Type RESULT
PMID: 15097290 (View on PubMed)

Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry. 2005 Sep;76(9):1188-93. doi: 10.1136/jnnp.2005.065334.

Reference Type RESULT
PMID: 16107348 (View on PubMed)

Schupbach WM, Maltete D, Houeto JL, du Montcel ST, Mallet L, Welter ML, Gargiulo M, Behar C, Bonnet AM, Czernecki V, Pidoux B, Navarro S, Dormont D, Cornu P, Agid Y. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology. 2007 Jan 23;68(4):267-71. doi: 10.1212/01.wnl.0000250253.03919.fb. Epub 2006 Dec 6.

Reference Type RESULT
PMID: 17151341 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BG200911

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.